Certifications, Presentation of Study Results and Earnings Releases - Research Report on Agilent, Mindray, Bard, Tornier, and

Certifications, Presentation of Study Results and Earnings Releases - Research
       Report on Agilent, Mindray, Bard, Tornier, and Life Technologies

PR Newswire

NEW YORK, November 11, 2013

NEW YORK, November 11, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Agilent
Technologies Inc. (NYSE: A), Mindray Medical International Ltd (NYSE: MR),
C.R. Bard, Inc. (NYSE: BCR), Tornier N.V. (NASDAQ: TRNX), and Life
Technologies Corp. (NASDAQ: LIFE). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Agilent Technologies Inc. Research Report

On November 6, 2013, Agilent Technologies Inc. (Agilent) announced that the
first near field communication (NFC) controller chipset developed by Shanghai
Fudan Microelectronics, FM 1930 chip, has successfully achieved NFC Forum
certification using Agilent RIDER T3111S RFID HF Conference Test System.
According to the Company, Shanghai Integrated Circuit Technology & Industry
Promotion Center (ICC) cooperated with TA Certification Lab and used NFC
Forum-validated test equipment from Agilent to perform the NFC Forum digital
certification. "We appreciate the professional technical support from Agilent,
ICC and TA during this certification process," said Mr. Liu Yifei, Assistant
General Manager of Shanghai Fudan Microelectronics Group. "Our certification
demonstrates the compliance of our NFC controller chipsets and is a key
milestone in our NFC strategy. We are the only vendor that can provide the NFC
controller chip in mainland China. Having added NFC SE and NFC Tag chips, we
now offer a complete NFC chip solution for our customers both here and
abroad." The Full Research Report on Agilent Technologies Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

[http://www.analystscorner.com/r/full_research_report/075e_A]

--

Mindray Medical International Ltd Research Report

On November 4, 2013, Mindray Medical International Ltd (Mindray) announced its
Q3 2013 results with net revenues of $296.3 million, up 15.3% YoY. Non-GAAP
net income stood at $57.4 million, reflecting an increase of 14.5% YoY. "In
the third quarter, we reported solid top-line growth. We are particularly
happy with our continued strong sales performance in Western Europe. Certain
key emerging markets also continued to do well, although demand in some
countries remained soft due to external factors. In China, the recent weak
market sentiment in the healthcare sector has caused some delays in purchasing
activities in the third quarter. However, the industry fundamentals remain
solid," said Mr. Li Xiting, Mindray's President and Co-CEO. "Reagent sales
continued to climb this quarter, highlighting our success in ramping up this
recurring IVD revenue." The Full Research Report on Mindray Medical
International Ltd - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/8d4d_MR]

--

C.R. Bard, Inc Research Report 

On October 30, 2013, C.R. Bard, Inc (Bard) reported that Kenneth Rosenfield,
M.D., Section Head for Vascular Medicine and Intervention, Massachusetts
General Hospital and LEVANT 2 Co-Primary Investigator, presented data related
to the study design, demographics, and six-month follow-up results from the
patients randomized in the LEVANT 2 Lutonix Drug-Coated Balloon (DCB) trial,
at the Transcatheter Cardiovascular Therapies (TCT) conference in San
Francisco, California. The Company informed that the follow-up results from
randomized patients, treated with the Lutonix DCB demonstrated safety
comparable to uncoated balloons (94.0% vs 94.1%) and superior primary patency
(92.3% vs 82.7%, p=0.003) by Kaplan-Meier time-to-event analysis. According to
Bard, interested parties may access the presentation slides at the Company
website, which will be available for a limited time period. The Full Research
Report on C.R. Bard, Inc - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/141e_BCR]

--

Tornier N.V. Research Report

On November 5, 2013, Tornier N.V. (Tornier) released its Q3 FY 2013 financial
results (period ended September 29, 2013) with revenues of $66.7 million, up
15.1% YoY. Q3 FY 2013 revenue of the Company's extremities product categories
totaled $56.9 million, compared to $48.7 million in Q3 FY 2012. Tornier also
reported that non-GAAP gross margins improved to 74.2% in Q3 FY 2013 from
73.4% in Q3 FY 2012. Dave Mowry, President and CEO of Tornier, said, "We
delivered adjusted EBITDA within our guidance range despite the lower than
expected revenue. This was driven by an improvement in non-GAAP gross margin
and prudent management of operating expenses. We believe we have the
infrastructure in place to support our double-digit constant currency revenue
growth and enhanced operating leverage expectations." Tornier stated that for
Q4 FY 2013 it expects constant currency revenue to range between $73 million
to $77 million. The Full Research Report on Tornier N.V. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

[http://www.analystscorner.com/r/full_research_report/b34f_TRNX]

--

Life Technologies Corp. Research Report

On November 5, 2013, Life Technologies Corp (Life Technologies) announced its
Q3 2013 financial results. The Company's revenues increased 2.6% YoY to $935.1
million, driven by increases in the Company's Research Consumables and
Bioproduction businesses, partially offset by declines in Genetic Analysis.
GAAP net income was $180 million in Q3 2013, compared to net income of 65.6
million in Q3 2012. Meanwhile, non-GAAP EPS for the quarter increased 10.9%
YoY to $1.02 in Q3 2013. "We are pleased with our mid-single digit revenue and
double-digit non-GAAP EPS growth, which was driven by strength across our
Research Consumables and Applied Sciences business groups, solid growth in
Japan and emerging markets such as China, and continued stability in the U.S.
and Europe," said Gregory T. Lucier, Chairman and CEO of Life Technologies.
The Full Research Report on Life Technologies Corp. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

[http://www.analystscorner.com/r/full_research_report/d5de_LIFE]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://AnalystsCorner.com



SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.